503a retatrutide Retatrutide: Benefits, Mechanism & Research

The precaution exists out of abundance of caution

Semaglutide (Ozempic/Wegovy) Timeline Phase 3 trials began: 2015 (SUSTAIN program for diabetes) FDA approval (Ozempic for diabetes): December 2017 Commercial availability: Early 2018 Wegovy (obesity indication) Phase 3: 2018-2020 (STEP program) Wegovy FDA approval: June 2021 Wegovy commercial launch: September 2021, immediately went into shortage due to overwhelming demand Stable widespread availability: Mid-2023 (after Novo Nordisk scaled up manufacturing) Total time from Phase 3 start to stable availability: About 8 years for diabetes indication, 5 years for obesity indication (but with significant supply constraints)

The 14-day plan costs $153 per week for a weekly meal guide, 14 breakfasts, 14 lunches, 14 dinners, 14 snacks and desserts, and 14 bars

Stopping peptide therapy generally does not blunt the bodys baseline growth hormone production, but these medications can still carry risks

13 Novo Nordisk resubmitted Wegovy for a heart failure with preserved ejection fraction indication in early 2025 with an FDA decision originally anticipated in the second half of 2025, subsequently delayed into 2026

Read the letter, and learn about this issue on our PBM page